Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.57 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | CCKBR | P32239 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198143 | 0.83 | NOTUM (0.45) | KCNN4KCNA3OPRK1KCNH2NR1I2 | |
| SCHEMBL7789691 | 0.78 | KCNN4 (0.66) | KCNN4KCNA3OPRK1KCNH2NR1I2 | |
| SCHEMBL332191 | 0.75 | KCNN4 (0.61) | KCNN4KCNA3OPRK1KCNH2NR1I2 | |
| SCHEMBL41130 | 0.73 | KCNN4 (1.00) | KCNN4KCNA3OPRK1KCNH2NR1I2 | |
| SCHEMBL29499525 | 0.73 | KCNN4 (1.00) | KCNN4KCNA3OPRK1KCNH2NR1I2 | |
| SCHEMBL4876723 | 0.72 | NOTUM (0.38) | CYP3A4TSHRNPSR1MEN1KMT2A | |
| Phenylboronic Acid SCHEMBL988758 | 0.72 | CA4 (0.44) | NPSR1CA2NOTUMCYP11B1CYP11B2 | |
| SCHEMBL16975525 | 0.71 | KIF11 (0.37) | KCNH2CYP3A4TSHRNPSR1KMT2A | |
| SCHEMBL2388992 | 0.71 | KCNN4 (0.60) | KCNN4KCNA3OPRK1KCNH2NR1I2 | |
| SCHEMBL16965740 | 0.70 | KCNN4 (0.58) | KCNN4KCNA3OPRK1KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358750-B1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-11 | — | — | EP | claimed |
| US-9428568-B2 | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | claimed |
| CN-102272152-B | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels | BOEHRINGER INGELHEIM INT | 2014-05-28 | — | — | CN | claimed |
| US-20110300152-A1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | YALE UNIVERSITY (US) | 2011-12-08 | — | — | US | claimed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | claimed |
| EP-2358750-A2 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | Boehringer Ingelheim International GmbH (DE) | 2011-08-24 | — | — | EP | claimed |
| WO-2010053584-A2 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-14 | — | — | WO | claimed |
| US-20090306159-A1 | Inhibition of Intermediate-Conductance Calcium Activated Potassium Channels in the Treatment and/or Prevention of Atherosclerosis | THE REGENTS OF THE UNIVERSITY (US) | 2009-12-10 | — | — | US | claimed |
| EP-1924259-A4 | INHIBITION OF INTERMEDIATE-CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNELS IN THE TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS | UNIV CALIFORNIA (US) | 2009-04-01 | — | — | EP | claimed |
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | claimed |
| EP-1924259-A2 | INHIBITION OF INTERMEDIATE-CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNELS IN THE TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS | The Regents of the University of California (US) | 2008-05-28 | — | — | EP | claimed |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-12-20 | — | — | US | claimed |
| WO-2007033307-A2 | INHIBITION OF INTERMEDIATE-CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNELS IN THE TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-22 | — | — | WO | claimed |
| EP-1562590-A4 | COMPOUNDS, METHODS AND DEVICES FOR INHIBITING NEOPROLIFERATIVE CHANGES IN BLOOD VESSEL WALLS | UNIV CALIFORNIA (US) | 2006-04-05 | — | — | EP | claimed |
| EP-1562590-A2 | COMPOUNDS, METHODS AND DEVICES FOR INHIBITING NEOPROLIFERATIVE CHANGES IN BLOOD VESSEL WALLS | The Regents of the University of California (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1248614-A4 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | UNIV CALIFORNIA (US) | 2005-05-04 | — | — | EP | claimed |
| US-6803375-B1 | IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | claimed |
| WO-2004039330-A2 | COMPOUNDS, METHODS AND DEVICES FOR INHIBITING NEOPROLIFERATIVE CHANGES IN BLOOD VESSEL WALLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-05-13 | — | — | WO | claimed |
| EP-1248614-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | The Regents of The University of California (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001049663-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-07-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | PGF, VEGFA, MKI67 | KCNN4 4235/4885KCNA3 4627/4885OPRK1 2639/4885 |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | NFATC1, ORAI1, KCNMA1 | KCNN4 10/4885KCNA3 46/4885OPRK1 799/4885 |
| US-20110300152-A1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | KCNN3, KCNN4, KCNMA1 | KCNN4 2/4885KCNA3 24/4885OPRK1 1404/4885 |
| US-20090306159-A1 | Inhibition of Intermediate-Conductance Calcium Activated Potassium Channels in the Treatment and/or Prevention of Atherosclerosis | KCNN3, KCNN1, KCNN4 | KCNN4 3/4885KCNA3 19/4885OPRK1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.